Obesity paradox in acute myocardial infarction: Is plasminogen activator inhibitor 1 the culprit?
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Obesity paradox in acute myocardial infarction: Is plasminogen activator inhibitor 1 the culprit?
Authors
Keywords
-
Journal
MEDICAL HYPOTHESES
Volume 176, Issue -, Pages 111096
Publisher
Elsevier BV
Online
2023-05-13
DOI
10.1016/j.mehy.2023.111096
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Impact of Obesity on Microvascular Obstruction and Area at Risk in Patients After ST-Segment-Elevation Myocardial Infarction: A Magnetic Resonance Imaging Study
- (2022) Di-Hui Lan et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Levels of TNF-α and Soluble TNF Receptors in Normal-Weight, Overweight and Obese Patients with Dilated Non-Ischemic Cardiomyopathy: Does Anti-TNF Therapy Still Have Potential to Be Used in Heart Failure Depending on BMI?
- (2022) Elżbieta Lazar-Poloczek et al. Biomedicines
- A Serpin With a Finger in Many PAIs: PAI-1's Central Function in Thromboinflammation and Cardiovascular Disease
- (2021) Gael B. Morrow et al. Frontiers in Cardiovascular Medicine
- The obesity paradox revisited: body mass index and long-term outcomes after PCI from a large pooled patient-level database
- (2020) Rafal Wolny et al. EuroIntervention
- Drug Targeting of Plasminogen Activator Inhibitor-1 Inhibits Metabolic Dysfunction and Atherosclerosis in a Murine Model of Metabolic Syndrome
- (2020) Hekmat B. Khoukaz et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- A Noncanonical Role for Plasminogen Activator Inhibitor Type 1 in Obesity-Induced Diabetes
- (2019) Gina M. Coudriet et al. AMERICAN JOURNAL OF PATHOLOGY
- Plasminogen activator inhibitor 1 in acute coronary syndromes
- (2019) Marin Pavlov et al. CLINICA CHIMICA ACTA
- Survival Benefit of Obese Patients With Pulmonary Embolism
- (2019) Karsten Keller et al. MAYO CLINIC PROCEEDINGS
- Plasminogen activator inhibitor-1 activity and long-term outcome in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention: a prospective cohort study
- (2018) Marin Pavlov et al. CROATIAN MEDICAL JOURNAL
- The obesity paradox is still there: a risk analysis of over 15 000 cardiosurgical patients based on body mass index
- (2017) Martin Hartrumpf et al. Interactive Cardiovascular and Thoracic Surgery
- Adiponectin as a Link Between Type 2 Diabetes and Vascular NADPH Oxidase Activity in the Human Arterial Wall: The Regulatory Role of Perivascular Adipose Tissue
- (2015) Alexios S. Antonopoulos et al. DIABETES
- PAI at breakfast (whether you like it or not)
- (2014) M. E. Young BLOOD
- Obesity Paradox Does Exist
- (2013) V. Hainer et al. DIABETES CARE
- Moderate overweight is beneficial and severe obesity detrimental for patients with documented atherosclerotic heart disease
- (2013) Aziza Azimi et al. HEART
- Time-course microarrays reveal early activation of the immune transcriptome and adipokine dysregulation leads to fibrosis in visceral adipose depots during diet-induced obesity
- (2012) Eun-Young Kwon et al. BMC GENOMICS
- Obesity paradox in Korean patients undergoing primary percutaneous coronary intervention in ST-segment elevation myocardial infarction
- (2009) Won Yu Kang et al. Journal of Cardiology
- Adiponectin: from obesity to cardiovascular disease
- (2009) C. Antoniades et al. Obesity Reviews
- Effect of tiplaxtinin (PAI-039), an orally bioavailable PAI-1 antagonist in a rat model of thrombosis
- (2008) J. K. Hennan et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now